-
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trialFeres F, Costa RA, OPTIMIZE Trial Investigators. -
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art ReviewD Capodanno, F Alfonso, GN Levine et al.
-
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPTPaolo Z; Liefke C; van der Heijden et al.
-
P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary InterventionPW Chen, WH Feng, MY Ho et al.
-
Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapyNakamura M, Kougame N, Iijima R et al.
-
Prasugrel versus clopidogrel in patients with acute coronary syndromesWiviott SD, Braunwald E, TRITON-TIMI 38 Investigators.
-
Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysisMC Baker, YJ Weng, RH William et al.
-
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-AnalysisM Valgimigli , R Mehran, SIDNEY Collaboration et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
